Free newsletter
The Peptide Research Digest
Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.
Prices, providers, and published evidence — tracked independently, never an affiliate code. Get research updates as the data grows.
Free · occasional research updates only · unsubscribe in one click
Already a member? Sign in
Peptide Profile
Growth Hormone Releasing Peptide 2 · Pralmorelin · GHRP2
GHRP-2 (growth hormone-releasing peptide-2; pralmorelin; KP-102) is a synthetic hexapeptide (D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH2) and potent ghrelin receptor (GHS-R1a) agonist developed as a GH secretagogue with established…
Educational research information — not medical advice. Review primary sources and consult a qualified professional before any decision.
Educational research tools — not medical advice.
Synthetic hexapeptide that stimulates pulsatile growth hormone release from the anterior pituitary by acting on the ghrelin receptor (GHSR-1a). Commonly stacked with GHRH analogs such as CJC-1295 or Sermorelin to amplify GH output synergistically.
GHRP-2 (growth hormone-releasing peptide-2; pralmorelin; KP-102) is a synthetic hexapeptide (D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH2) and potent ghrelin receptor (GHS-R1a) agonist developed as a GH secretagogue with established efficacy in stimulating pulsatile GH release from pituitary somatotrophs, characterized by potent GH stimulation alongside non-selective co-stimulation of cortisol and prolactin secretion. As a first-generation GHRP, GHRP-2 achieves its GH-secretory effect through direct GHS-R1a agonism with amplification by endogenous GHRH; it is distinguished from later selective GHRPs such as ipamorelin by its non-selective endocrine profile, and synergistic GH stimulation is observed when combined with GHRH analogs in diagnostic protocols. GHRP-2 has been validated as a diagnostic agent for the GHRP-2 stimulation test used in Japan to assess GH secretion capacity in adults with suspected hypopituitarism or post-surgical pituitary dysfunction, with published human clinical data supporting its reliability as a GH stimulation tool in endocrine diagnostic practice. GHRP-2 has no FDA approval for any therapeutic or diagnostic indication in the United States; it is used diagnostically in Japan and as a research compound elsewhere, with no approved indication for GH enhancement, performance, or anti-aging applications, and its non-selective endocrine stimulation profile represents a relevant consideration versus more selective GH secretagogues. GHRP-2 and GHRH combination research: co-administration with a GHRH analog (such as CJC-1295 or sermorelin) produces synergistic GH release through complementary receptor mechanisms and is studied in combination protocols for this reason. Subcutaneous injection is the standard administration route in research contexts. GHRP-2 vs GHRP-6 vs ipamorelin: GHRP-2 produces potent GH release but with co-stimulation of cortisol and prolactin, similar to GHRP-6. The key distinguishing feature of GHRP-6 is stronger appetite stimulation (ghrelin-like effect); GHRP-2 produces less appetite stimulation with comparable or slightly greater GH output per dose. Both are non-selective compared to ipamorelin, which was developed specifically to achieve GH stimulation without the cortisol and prolactin co-elevation that characterizes first-generation GHRPs. For research contexts prioritizing GH selectivity, ipamorelin is generally preferred; GHRP-2 is used where its diagnostic validation and potent GH stimulation profile are the research objectives.
Commonly researched in the context of
Population research notes
These signals reflect research interest areas, not treatment indications.
Compound & timing
Model: single-dose, first-order (single-compartment) estimate. Real clearance is multi-compartment and varies by individual and route.
based on 2 studies · most recent 2020
Approved for diagnostic GH stimulation testing in Japan (Kaken Pharma) but NOT FDA-approved. Listed on the FDA Category 2 'significant safety risks' bulk-substances list (503B designation, added September 2023). WADA prohibited. Research chemical in US.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
2 sources cited · 2 moderate
1 Cohort · 1 Review
Preoperative growth hormone (GH) peak values during a GH releasing peptide-2 test reflect the severity of hypopituitarism and the postoperative recovery of GH secretion in patients with non-functioning pituitary adenomas
Endocrine Journal · 2020
Research in 76 patients with non-functioning pituitary adenomas found that preoperative GHRP-2 stimulation test peak GH values correlated with the severity of anterior pituitary hormone deficiency and predicted postoperative recovery of GH secretion, validating GHRP-2 as a sensitive diagnostic tool for assessing somatotropic axis integrity.
Adult growth hormone deficiency: current concepts
Neurologia Medico-Chirurgica · 2014
This review describes the clinical diagnosis and treatment of adult growth hormone deficiency, noting that the GHRP-2 stimulation test reliably evaluates GH secretory capacity in adults and that GH replacement therapy improves body composition, dyslipidemia, and quality of life in deficient patients.
No FDA-approved label for this compound. Cautions below are extrapolated from its mechanism/drug class — investigational; educational only.
Absolute contraindications
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
Common monitoring markers in research protocols
GHRP-2 stimulates GH and cortisol release. Research protocols measure IGF-1 for GH axis response and baseline cortisol given the compound's adrenal stimulation. Glucose markers are standard given GH's effect on insulin sensitivity.
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Pharmaceutical interactions are noted for research awareness. Always consult your prescriber before combining GHRP-2 with any medication.
Research notes that GHRP-2 stimulates cortisol and ACTH release via the HPA axis. Combined use with corticosteroid medications may affect glucocorticoid regulation. Consult your prescriber before combining.
Arvat E et al. (1998) GHRP-2 stimulates ACTH and cortisol secretion. J Clin Endocrinol Metab; Ghigo E et al. (1997) GH secretagogues and the HPA axis. Metabolism
These interactions reflect published research and are provided for educational purposes only. This is not medical advice. Consult a qualified healthcare professional before combining any compounds or medications.
GHRP-2 · Lot GH202 · May 6, 2026
PeptideBase reports these lab-published figures and does not itself test, endorse, or certify any product. Verified results come from an independent third-party lab database lookup. Vendor-published results are reported by the vendor itself and have not been independently verified by PeptideBase or a third-party lab.
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.
GHRP-2 (growth hormone-releasing peptide-2; pralmorelin; KP-102) is a synthetic hexapeptide (D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH2) and potent ghrelin receptor (GHS-R1a) agonist developed as a GH secretagogue with established efficacy in stimulating pulsatile GH release from pituitary somatotrophs, characterized by potent GH stimulation alongside non-selective co-stimulation of cortisol and prolactin secretion. As a first-generation GHRP, GHRP-2 achieves its GH-secretory effect through direct GHS-R1a agonism with amplification by endogenous GHRH; it is distinguished from later selective GHRPs such as ipamorelin by its non-selective endocrine profile, and synergistic GH stimulation is observed when combined with GHRH analogs in diagnostic protocols.
potent GH release via GHS-R1a agonism, co-stimulation of cortisol and prolactin (non-selective profile), synergistic GH amplification when combined with GHRH analogs, validated diagnostic GH stimulation agent (Japan clinical use).
Research on GHRP-2 primarily documents effects related to potent GH release via GHS-R1a agonism and co-stimulation of cortisol and prolactin (non-selective profile) and synergistic GH amplification when combined with GHRH analogs and validated diagnostic GH stimulation agent (Japan clinical use). These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
For GHRP-2, its FDA status is banned from compounding by the FDA, and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
34 providers in the directory currently offer GHRP-2.
Across 28 research vendors tracked on PeptideBase, GHRP-2 has a median price of about $5.95 per mg, typically ranging $3.92–$8.00 per mg. This reflects research-use vendor pricing, not clinical or prescription costs.
Research in 76 patients with non-functioning pituitary adenomas found that preoperative GHRP-2 stimulation test peak GH values correlated with the severity of anterior pituitary hormone deficiency and predicted postoperative recovery of GH secretion, validating GHRP-2 as a sensitive diagnostic tool for assessing somatotropic axis integrity.
GHRP-2 is featured in the following research stacks on PeptideBase: Sermorelin + GHRP-2: GH Stimulation & Recovery.
Price per mg varies by quantity, vendor type, and formulation. Research use only.
Data verified July 2026 · GHRP-2 price intelligence
Clinic Infinity
Medical Anti-Aging
Protocol Health
Revitalize IV Solutions & MedSpa
The Perito Clinic
Vital Force IV Therapy Hoover AL
Dr. Louis Peter Re, JR
Impact Health
Premier TRT
Pura Vida Body & Mind Spa
Commonly stacked with
Stay updated on verified GHRP-2 providers
New verified providers added weekly — delivered to your inbox.
Last updated
Keep exploring
Tools & Guides
Reconstitution Calculator
Convert vial size + BAC water volume into draw volume.
How to Reconstitute Peptides
Step-by-step guide: BAC water, vial prep, and storage after mixing.
Peptide Dosage Guide
Key factors that determine dosing in clinical practice.
Peptide Storage Guide
How to store lyophilized and reconstituted peptides.
Data last updated July 20, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). GHRP-2 — Per-mg Price Benchmark. Retrieved July 22, 2026, from https://peptidebase.io/peptides/ghrp-2